GCM
CYTK icon

Ghisallo Capital Management’s Cytokinetics CYTK Stock Holding History

Ghisallo Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-196,000
Closed -$10.6M – 153
2024
Q2 		$10.6M Buy
+196,000
New +$11.8M 0.92% 26

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Ghisallo Capital Management's CYTK Position: Q3 2024 in Review

Ghisallo Capital Management sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 196,000 shares — an estimated $10.6M sold.

Ghisallo Capital Management first reported a position in CYTK in Q2 2024 and held it in 1 quarter. The position peaked at $10.6M in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Ghisallo Capital Management reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Ghisallo Capital Management sold 196,000 Cytokinetics shares in Q3 2024, an estimated $10.6M.
  • Ghisallo Capital Management first reported a position in Cytokinetics in Q2 2024 and held it in 1 quarter.
  • Ghisallo Capital Management's Cytokinetics position peaked at $10.6M in Q2 2024.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Ghisallo Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.